UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has announced it will provide a corporate update for Q2 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time to discuss financial results and provide an overview. Investors can join the call toll-free at 1-800-717-1738, and a webcast link is available. A replay of the call will be accessible on the Events section of Cellectar's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biofarmaceutica in fase avanzata focalizzata sul trattamento del cancro, ha annunciato che fornirà un aggiornamento aziendale per il Q2 2024 martedì 13 agosto 2024. L'azienda ospiterà una teleconferenza e un webcast alle 8:30 ora orientale per discutere i risultati finanziari e fornire una panoramica. Gli investitori possono partecipare alla chiamata senza costi al numero 1-800-717-1738, ed è disponibile un link per il webcast. Una registrazione della chiamata sarà accessibile nella sezione Eventi del sito web delle relazioni con gli investitori di Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarmacéutica en etapa avanzada enfocada en el tratamiento del cáncer, ha anunciado que proporcionará una actualización corporativa para el Q2 2024 el martes 13 de agosto de 2024. La empresa llevará a cabo una llamada de conferencia y un webcast a las 8:30 a.m. hora del Este para discutir los resultados financieros y ofrecer una visión general. Los inversores pueden unirse a la llamada sin costo al 1-800-717-1738, y hay un enlace disponible para el webcast. Una repetición de la llamada estará accesible en la sección de Eventos del sitio web de relaciones con los inversores de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB)는 암 치료에 중점을 둔 후기 단계 임상 생명공학 회사로, 2024년 2분기 기업 업데이트를 2024년 8월 13일 화요일에 제공할 것이라고 발표했습니다. 회사는 동부 표준시 기준 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 개최하여 재무 결과를 논의하고 개요를 제공할 예정입니다. 투자자는 1-800-717-1738번으로 무료로 통화에 참여할 수 있으며, 웹캐스트 링크도 제공됩니다. 통화 재방송은 Cellectar의 투자자 관계 웹사이트의 이벤트 섹션에서 접근할 수 있습니다.
Cellectar Biosciences (NASDAQ: CLRB), une entreprise biopharmaceutique en phase avancée axée sur le traitement du cancer, a annoncé qu'elle fournirait une mise à jour d'entreprise pour le T2 2024 le mardi 13 août 2024. L'entreprise organisera une conférence téléphonique et un webcast à 8h30, heure de l'Est, pour discuter des résultats financiers et donner un aperçu. Les investisseurs peuvent rejoindre l'appel sans frais au 1-800-717-1738, et un lien pour le webcast est disponible. Un replay de l'appel sera accessible dans la section Événements du site web des relations investisseurs de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung von Krebs konzentriert, hat angekündigt, am Dienstag, den 13. August 2024, ein Corporate Update für Q2 2024 anzubieten. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und einen Überblick zu geben. Investoren können kostenlos unter 1-800-717-1738 an der Konferenz teilnehmen, und ein Link zum Webcast ist verfügbar. Eine Wiederholung der Konferenz wird im Bereich Events der Investor-Relations-Website von Cellectar zugänglich sein.
- None.
- None.
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
Conference Call & Webcast Details:
Date: Tuesday, August 13, 2024
Time: 8:30 am Eastern Time
Toll Free: 1-800-717-1738
Webcast: Click HERE
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
FAQ
When will Cellectar Biosciences (CLRB) announce its Q2 2024 financial results?
What time is Cellectar Biosciences' (CLRB) Q2 2024 earnings call scheduled for?
How can investors access Cellectar Biosciences' (CLRB) Q2 2024 earnings call?
What is Cellectar Biosciences' (CLRB) primary focus as a company?
